Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q4 FY23 results · Jan–Mar 2023
Procter & Gamble Health reported revenue from operations of ₹320.92 crore (up 19.8% from Q4 FY22) and net profit of ₹59.19 crore (up 15.7% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 320.92 | 267.82 | +19.8% | 309.97 | +3.5% |
| Other income | 4.97 | 2.35 | +111.5% | 4.54 | +9.5% |
| Total income | 325.89 | 270.17 | +20.6% | 314.51 | +3.6% |
| Profit before tax | 78.53 | 64.86 | +21.1% | 104.94 | −25.2% |
| Net profit for the period | 59.19 | 51.16 | +15.7% | 76.80 | −22.9% |
| EPS, basic (₹) | 35.70 | 30.80 | +15.9% | 46.30 | −22.9% |
| Net margin (%) | 18.4 | 19.1 | 24.8 |
Standalone
- Filed with BSE
- 16 May 2023, 15:20 IST
- Board meeting
- 15 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE